|
 Ampyra, which was approved in January 2010, had net sales of $72.5
million in the first quarter ended March 31.
Acorda said Actavis has submitted a marketing approval application
with the U.S. Food and Drug Administration for a generic version of
the drug.
Acorda said it intends to vigorously defend its intellectual
property rights.
(Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
